TY - JOUR
T1 - Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response
T2 - a pooled analysis of a multicenter clinical trial (KSCC 1605-A)
AU - Sasaki, Shun
AU - Oki, Eiji
AU - Saeki, Hiroshi
AU - Shimose, Takayuki
AU - Sakamoto, Sanae
AU - Hu, Qingjiang
AU - Kudo, Kensuke
AU - Tsuda, Yasuo
AU - Nakashima, Yuichiro
AU - Ando, Koji
AU - Akagi, Yoshito
AU - Kakeji, Yoshihiro
AU - Baba, Hideo
AU - Maehara, Yoshihiko
N1 - Funding Information:
This study received no financial or material support. The authors thank the following institutions and investigators who participated in this study: Baba H (Kumamoto University Hospital), Kakeji Y (Kobe University Hospital), Akagi Y (Kurume University Hospital), Ogata Y (Kurume University Hospital), Eguchi S (Nagasaki University Hospital), Nishimaki T (Ryukyu University Hospital), and Natsugoe S (Kagoshima University Hospital). We also thank Sakamoto S and the staff at the Clinical Research Support Center Kyushu (CReS Kyushu) for their excellent data collection and management and secretarial assistance. We thank Shimose T for the statistical analysis. This work was supported by CReS Kyushu with no funding. We would like to thank Editage (https://www.editage.jp ) for English language editing.
Publisher Copyright:
© 2019, Japan Society of Clinical Oncology.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Background: Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC). Methods: A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9%) were evaluated. Results: Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference (P < 0.01); however, baseline sarcopenia was not associated with prognosis. SML at 3 months was associated with an incidence of adverse events (P = 0.01), poor objective response rate (ORR) (P < 0.01), and poor progression-free survival (PFS) (P = 0.03), and it was an independent predictive factor for poor ORR (P < 0.01) and PFS (P = 0.04). Conclusion: SML at 3 months after systemic chemotherapy for mCRC was associated with poor treatment response. Thus, clarifying the importance of SML prevention guarantees a more effective chemotherapy.
AB - Background: Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC). Methods: A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9%) were evaluated. Results: Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference (P < 0.01); however, baseline sarcopenia was not associated with prognosis. SML at 3 months was associated with an incidence of adverse events (P = 0.01), poor objective response rate (ORR) (P < 0.01), and poor progression-free survival (PFS) (P = 0.03), and it was an independent predictive factor for poor ORR (P < 0.01) and PFS (P = 0.04). Conclusion: SML at 3 months after systemic chemotherapy for mCRC was associated with poor treatment response. Thus, clarifying the importance of SML prevention guarantees a more effective chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85065325729&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065325729&partnerID=8YFLogxK
U2 - 10.1007/s10147-019-01460-8
DO - 10.1007/s10147-019-01460-8
M3 - Article
C2 - 31062115
AN - SCOPUS:85065325729
SN - 1341-9625
VL - 24
SP - 1204
EP - 1213
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 10
ER -
